PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin.

ABSTRACT:

Background

The success of new targeted cancer therapies has been dependent on the identification of tumor-specific antigens. Podocalyxin (Podxl) is upregulated on tumors with high metastatic index and its presence is associated with poor outcome, thus emerging as an important prognostic and theragnostic marker in several human cancers. Moreover, in human tumor xenograft models, Podxl expression promotes tumor growth and metastasis. Although a promising target for immunotherapy, the expression of Podxl on normal vascular endothelia and kidney podocytes could hamper efforts to therapeutically target this molecule. Since pathways regulating post-translational modifications are frequently perturbed in cancer cells, we sought to produce novel anti-Podxl antibodies (Abs) that selectively

SUBMITTER: Canals Hernaez D 

PROVIDER: S-EPMC7692987 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature